Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,
Can weight loss drugs get people back to work? Eli Lilly wants to find out
Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help get some people back to work.
Can weight-loss drug help employment? This is how obesity drug Zepbound maker Eli Lilly can help UK
In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a trial assessing weight loss jabs' effects on employment, productivity, and heal
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
Minnesota firm acquires North Carolina lab from Catalent
A life sciences company has sold off part of its business that includes a Morrisville facility with hundreds of workers.
Novo Nordisk A/S (NVO): Most Promising Future Stock According to Analysts
We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
BioSpace6d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
MM&M1d
Pipeline Report 2024: See the life-changing therapies showing promise
Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...
3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo Nordisk: Mounting Challenges
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Behind the Scenes of Novo Nordisk's Latest Options Trends
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...